Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro) is an endogenous tetrapeptide that differs from nearly every other research peptide in one respect: its specific receptor has never been identified. Essentially all of its known pharmacology is described not through a receptor, but through the enzyme that destroys it, the N-terminal active site of angiotensin-converting enzyme (ACE).

Where the peptide comes from

Ac-SDKP is not the product of its own gene. It is the N-terminal fragment (residues 1–4) of thymosin β4, released enzymatically. The principal enzyme responsible is prolyl oligopeptidase, inhibiting it lowers plasma Ac-SDKP, which is how its role was established.[6] In the kidney an additional pathway involving meprin-α operates alongside prolyl oligopeptidase.[11]

This places Ac-SDKP on the axis thymosin β4 → prolyl oligopeptidase → Ac-SDKP → ACE, and explains why it is often mentioned alongside TB-500 (a fragment of the same precursor protein), although they are distinct molecules with distinct biology.

The enzyme that defines the peptide

In 1995 Ac-SDKP was shown to be a natural and highly specific substrate of the N-terminal of ACE's two catalytic domains.[2] This is an unusual case of domain selectivity: most ACE substrates, angiotensin I included, are hydrolysed by both domains. Later crystallographic work resolved the structural basis of that selectivity, how the N-domain recognises the tetrapeptide.[10]

The practical consequence proved far larger than the peptide itself. Because ACE is the dominant route of Ac-SDKP degradation, ACE-inhibitor therapy raises its plasma concentration roughly 5-fold. Plasma Ac-SDKP has even been proposed as a biomarker of adherence to ACE-inhibitor therapy, though that idea carries known limitations.[4] More importantly, it produced the hypothesis that part of the antifibrotic benefit of ACE inhibitors is mediated by Ac-SDKP accumulation rather than by angiotensin II reduction alone. That hypothesis remains unproven in humans.[8]

A clinical history that ran backwards

Here Ac-SDKP departs sharply from the typical "research peptide". Most such compounds have never been given to a human. Ac-SDKP has, but for an entirely different indication.

It was discovered in 1989 as an inhibitor of pluripotent haematopoietic stem cell proliferation: a natural negative regulator of haematopoiesis that reversibly holds stem cells out of S-phase.[1] From this came the chemoprotection concept, if cytotoxic drugs kill dividing cells, temporarily quiescing stem cells should shield the bone marrow. Under the names goralatide and seraspenide the compound reached phase I-II studies in cancer patients during the 1990s, with preclinical work demonstrating protection against doxorubicin toxicity.[3]

It never reached approval. The antifibrotic direction for which Ac-SDKP is known today emerged later and has never been tested in humans at all. The clinical experience that exists belongs to an abandoned haematological indication, not to the one that makes the peptide interesting now.

What the antifibrotic research actually shows

The data are overwhelmingly rodent and cell-culture. The best-characterised mechanism is interference with TGF-β1 signalling: Ac-SDKP suppresses phosphorylation of Smad2 in cardiac fibroblasts[5], acting on the canonical pathway by which TGF-β1 drives collagen production. Alongside this, suppression of fibroblast proliferation (delayed G0/G1 → S transition) has been reported, essentially the same antiproliferative effect seen in the haematological story, in a different cell type.

  • Heart, reduced fibrosis and inflammation in post-myocardial-infarction and hypertensive injury models.
  • Kidney, the most developed line of work, studied extensively in diabetic nephropathy models including oral administration in mice.
  • Lung, the bleomycin pulmonary fibrosis model, in both preventive and therapeutic dosing schedules.[12]

Anti-inflammatory and pro-angiogenic effects have also been described.[7] It should be stated plainly: these are preclinical models, and translation from them to humans has historically had a poor track record specifically in antifibrotic therapy.

Why it never became a drug

The decisive obstacle is pharmacokinetic. The circulating half-life of Ac-SDKP is roughly 4–5 minutes, the very ACE activity that makes the peptide interesting eliminates it almost immediately. Sustaining a meaningful concentration by exogenous administration is impractical.

The field's response was an elegant inversion: rather than administer the peptide, stop destroying it. Hence the effort to design N-domain-selective ACE inhibitors that would raise endogenous Ac-SDKP without blocking the C-domain, and therefore without the bradykinin accumulation associated with the cough and angioedema of classical ACE inhibitors. That programme, not the peptide itself, is the main practical outcome of the whole Ac-SDKP story.[9]

What remains unknown

  • No receptor identified. How the tetrapeptide reaches Smad2 remains incompletely explained.
  • No clinical trial in fibrosis. The entire antifibrotic evidence base is preclinical.
  • The ACE-inhibitor contribution hypothesis is unproven in humans: the rise in Ac-SDKP on ACE inhibitors is a correlation, not a demonstrated causal share of the clinical effect.
  • The antiproliferative action cuts both ways. A peptide that suppresses entry into S-phase is by definition not inert; the long-term consequences of that are uncharacterised.

Reference data

  • Sequence: Ac-Ser-Asp-Lys-Pro (N-acetylated tetrapeptide)
  • Formula: C20H33N5O9; molar mass ≈ 487.5 g/mol (free peptide; acetate salts are heavier)
  • CAS (Chemical Abstracts Service number): 120081-14-3; PubChem CID 65938
  • Other names: goralatide, seraspenide, Thymosin β4 (1–4)
  • Plasma half-life: ≈ 4–5 min (hydrolysis by the ACE N-domain)

Status

Ac-SDKP is a research-use-only laboratory reagent. It is not a medicine and not a dietary supplement; it is not approved by any regulatory authority for any indication, and it is not intended for human or animal consumption, or for the diagnosis, treatment or prevention of disease. The material above describes published scientific research; it is not medical advice and contains no dosing guidance.

Related material: the Anti-fibrosis category, the B7-33 monograph (a relaxin analogue, a different, receptor-mediated approach to fibrosis) and BPC-157 + TB-500 (TB-500 derives from the same thymosin β4).